Assist Prof Dr. Khalid Abd El Ghany, Egyption Drug Authoriity, Egypt
Dr. Khalid Abd El Ghany is a Post-Approval Control Manager at the Egyptian Drug Authority (since 2021) with over two decades of experience in the pharmaceutical sector. He holds a Ph.D. in Genetic Engineering and Biotechnology from Al-Sadat City University (2018) and has completed post-doctoral research at the Egyptian Drug Authority. He is a skilled researcher with numerous publications and expertise in microbial biotechnology. A recipient of the Egyptian Drug Authority Heroβs Certificate (2022) and the Ideal Pharmacist Award (2016), Dr. Khalid is also active in social initiatives, holding leadership roles in various organizations. ππ
Publication profile
Google Scholar
Education Background
Dr. Khalid Abd El Ghany has a distinguished educational background in pharmacy and biotechnology. He earned his B.Sc. in Pharmacy with honors from Al-Azhar University, Egypt, in 1994. Later, he pursued an M.Sc. in Microbial Biotechnology from Al-Sadat City University (2012-2014), further advancing his expertise with a Ph.D. in Genetic Engineering and Biotechnology from the same institution in 2018. Since 2020, he has been a post-doctoral researcher at the Egyptian Drug Authority, where he continues to contribute to the field of microbial biotechnology. ππ¬
Professional Experience
Dr. Khalid Abd El Ghany has extensive experience in pharmaceutical regulation and management. Since 2021, he has served as the Post-Approval Control Manager at the Egyptian Drug Authority (EDA). From 2017 to 2021, he was the Deputy Head of the Inspection Department at NODCAR, where he also worked in the Microbiology Lab from 2012 to 2017. His career began as a pharmacist at Arab Drug Company (1995-1996), followed by years in the private pharmaceutical sector, where he was the owner and director from 1996 to 2011. ππ¬
Research Focus
Dr. Khalid Abd El Ghanyβs research is primarily centered on microbial biotechnology and genetic engineering. His work involves probiotics, especially Lactobacillus acidophilus, in cancer treatment and antioxidant activities. He also focuses on vaccine design, integrating immunoinformatics and cheminformatics to target pathogens like Klebsiella pneumoniae and Pseudomonas aeruginosa. Additionally, Dr. Khalid has contributed to studies on Ξ²-glucan production, antimicrobial agents, and the potential of probiotics against viral infections, including COVID-19. His work is diverse, covering biotechnology, immunology, and pharmaceutical sciences. π§¬π
Conclusion
With his strong academic background, significant experience in pharmaceutical regulation, a proven track record in research, and leadership in social initiatives, Assist. Prof. Dr. Khalid Abd El Ghany is a strong candidate for the Best Researcher Award. His dedication to both scientific advancement and community service makes him a well-rounded contender for this recognition.
Publication Top Notes
- A potential role of Lactobacillus acidophilus LA1 and its exopolysaccharides on cancer cells in male albino mice β 43 citations (2015) ππ§¬
- In Silico Designing of a Multitope Vaccine against Rhizopus microsporus β 26 citations (2021) ππ₯οΈ
- Evaluation of antioxidant and antitumor activities of Lactobacillus acidophilus bacteria β 20 citations (2014) π§ͺπ¦
- Screening and molecular identification of lactic acid bacteria producing Ξ²-glucan β 13 citations (2022) π§¬π
- Description of isolated LAB producing Ξ²-glucan and evaluation of its therapeutic effect β 11 citations (2016) π§«π©Ί
- Integration of Immunoinformatics and Cheminformatics for Vaccine Design β 5 citations (2023) π§¬π
- Molecular Characterization and Optimization of Ξ²-Glucan Production from Pediococcus parvulus β 3 citations (2018) π§¬π
- Lactiplantibacillus plantarum and Saussurea costus as Therapeutic Agents β 2 citations (2023) π§¬π
- Role of probiotic bacteria against virus pathogenesis: Defence against COVID-19 β 1 citation (2024) π¦ π§¬
- Efficacy of Ξ²-glucan in an acute model of diabetes β 1 citation (2022) π©Ίπ
- Synthesis, Molecular Docking Studies of Pyrazolo[1,5-a]pyrimidines β 2023 πβοΈ